HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Aurobindo Pharma Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Aurobindo Pharma Intelligence Report

Generated from 26 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Jul 22, 2026

Confidence

Moderate Confidence · 67%

Evidence

150 items

Sources

15

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Aurobindo Pharma maintains an active intelligence profile across Gastroenterology, IBS-D, Psychiatry, Antipsychotic, Neurology. 26 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 67% across 3 tracked sources. Highest-priority development: Internet Pharmacy Warning Letters. Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    Internet Pharmacy Warning Letters

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    Centaur Pharmaceuticals Private Ltd. - 651080 - 06/05/2023

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    Centaur Pharmaceuticals Private Ltd. - 651080 - 12/03/2025

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    Unique Pharmaceutical Laboratories (A Div.

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Internet Pharmacy Warning Letters

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    Wizcure Pharmaa Private Limited - 726378 - 06/24/2026

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 3212 with buyer quality 3 (Low Priority). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Internet Pharmacy Warning Letters

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Centaur Pharmaceuticals Private Ltd. - 651080 - 06/05/2023

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Centaur Pharmaceuticals Private Ltd. - 651080 - 12/03/2025

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Unique Pharmaceutical Laboratories (A Div.

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Internet Pharmacy Warning Letters

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Wizcure Pharmaa Private Limited - 726378 - 06/24/2026

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Internet Pharmacy Warning Letters

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Wizcure Pharmaa Private Limited - 726378 - 06/24/2026

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approval Status Update for Deutetrabenazine by Aurobindo Pharma

    Neurology · Movement Disorders

  • Aurobindo Pharma's Olanzapine ANDA203708 Receives AP Status from FDA

    Psychiatry · Antipsychotic

  • Aurobindo Pharma's Lacosamide ANDA209224 Receives AP Status from FDA

    Neurology · Antiepileptic

  • Aurobindo Pharma's Lacosamide ANDA204994 Receives AP Status from FDA

    Neurology · Antiepileptic

  • Aurobindo Pharma submits ANDA for Empagliflozin

    Diabetes · SGLT2 Inhibitor

  • Aurobindo Pharma's ANDA216537 for Carbidope and Levodopa Receives AP Status

    Neurology · Parkinson's Disease

  • Aurobindo Pharma's Aciclovir ANDA216331 Receives AP Status from FDA

    Infectious Disease · Antiviral

  • Aurobindo Pharma's Finasteride ANDA078341 Receives AP Status

    Urology · 5-alpha reductase inhibitor

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.